{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:24:02Z","timestamp":1794021842497,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07165-z","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:44:32Z","timestamp":1783669472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of non-opioid therapies for pain management of sickle cell disease: a literature-based review"],"prefix":"10.1007","volume":"105","author":[{"given":"Kayla","family":"Riley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7348-6369","authenticated-orcid":false,"given":"Rolake","family":"Neba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-9099","authenticated-orcid":false,"given":"Adenike","family":"Atanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"7165_CR1","doi-asserted-by":"publisher","unstructured":"GBD 2021 Sickle Cell Disease Collaborators (2023) Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol 10(8):e585\u2013e599. https:\/\/doi.org\/10.1016\/S2352-3026(23)00118-7","DOI":"10.1016\/S2352-3026(23)00118-7"},{"key":"7165_CR2","unstructured":"Centers for Disease Control and Prevention (2025) Sickle cell disease (SCD): data and statistics. https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html. Accessed December 16"},{"issue":"3","key":"7165_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1535370220976397","volume":"246","author":"L Hallmark","year":"2021","unstructured":"Hallmark L, Almeida LE, Kamimura S, Smith M, Quezado ZM (2021) Nitric oxide and sickle cell disease: is there a painful connection? Exp Biol Med (Maywood) 246(3):332\u2013341. https:\/\/doi.org\/10.1177\/1535370220976397","journal-title":"Exp Biol Med (Maywood)"},{"key":"7165_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.trsl.2021.03.007","volume":"234","author":"V Sagi","year":"2021","unstructured":"Sagi V, Mittal A, Tran H, Gupta K (2021) Pain in sickle cell disease: current and potential translational therapies. Transl Res 234:141\u2013158. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.007","journal-title":"Transl Res"},{"key":"7165_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2147\/JPR.S343069","volume":"15","author":"MO Kenney","year":"2022","unstructured":"Kenney MO, Smith WR (2022) Moving toward a multimodal analgesic regimen for acute sickle cell pain with non-opioid analgesic adjuncts: a narrative review. J Pain Res 15:879\u2013894. https:\/\/doi.org\/10.2147\/JPR.S343069","journal-title":"J Pain Res"},{"issue":"12","key":"7165_CR6","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","volume":"4","author":"AM Brandow","year":"2020","unstructured":"Brandow AM, Carroll CP, Creary S et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 4(12):2656\u20132701. https:\/\/doi.org\/10.1182\/bloodadvances.2020001851","journal-title":"Blood Adv"},{"issue":"8","key":"7165_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31788","volume":"72","author":"AJ Ologunowa","year":"2025","unstructured":"Ologunowa AJ, Matson KL, Lee JE, McCormick M, Greaney ML, Caffrey AR (2025) Medication utilization among children with sickle cell disease in the United States. Pediatr Blood Cancer 72(8):e31788. https:\/\/doi.org\/10.1002\/pbc.31788","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"7165_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40272-017-0263-z","volume":"20","author":"L Puri","year":"2018","unstructured":"Puri L, Nottage KA, Hankins JS, Anghelescu DL (2018) State-of-the-art management of acute vaso-occlusive pain in sickle cell disease. Paediatr Drugs 20(1):29\u201342. https:\/\/doi.org\/10.1007\/s40272-017-0263-z","journal-title":"Paediatr Drugs"},{"issue":"11","key":"7165_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00277-020-04205-0","volume":"99","author":"SK Ballas","year":"2020","unstructured":"Ballas SK, Dampier C (2020) Risk factors associated with increased emergency department utilization in patients with sickle cell disease: a systematic literature review. Ann Hematol 99(11):2483\u20132495. https:\/\/doi.org\/10.1007\/s00277-020-04205-0","journal-title":"Ann Hematol"},{"issue":"14","key":"7165_CR10","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","volume":"8","author":"S Lanzkron","year":"2024","unstructured":"Lanzkron S, Crook N, Wu J et al (2024) Costs and impact of disease in adults with sickle cell disease: a pilot study. Blood Adv 8(14):3629\u20133638. https:\/\/doi.org\/10.1182\/bloodadvances.2023012477","journal-title":"Blood Adv"},{"issue":"5","key":"7165_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jcpt.12592","volume":"42","author":"J Han","year":"2017","unstructured":"Han J, Saraf SL, Lash JP, Gordeuk VR (2017) Use of anti-inflammatory analgesics in sickle cell disease. J Clin Pharm Ther 42(5):656\u2013660. https:\/\/doi.org\/10.1111\/jcpt.12592","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"7165_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/hematology.2024000585","volume":"2024","author":"M Azul","year":"2024","unstructured":"Azul M, Brandow AM (2024) Beyond IV push: alternative methods for management of acute pain in SCD. Hematol Am Soc Hematol Educ Program 2024(1):611\u2013617. https:\/\/doi.org\/10.1182\/hematology.2024000585","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"10","key":"7165_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312(10):1033\u20131048. https:\/\/doi.org\/10.1001\/jama.2014.10517","journal-title":"JAMA"},{"issue":"2","key":"7165_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30089","volume":"70","author":"H Khan","year":"2023","unstructured":"Khan H, Krull M, Hankins JS, Wang WC, Porter JS (2023) Sickle cell disease and social determinants of health: a scoping review. Pediatr Blood Cancer 70(2):e30089. https:\/\/doi.org\/10.1002\/pbc.30089","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"7165_CR15","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","volume":"130","author":"H Tran","year":"2017","unstructured":"Tran H, Gupta M, Gupta K (2017) Targeting novel mechanisms of pain in sickle cell disease. Blood 130(22):2377\u20132385. https:\/\/doi.org\/10.1182\/blood-2017-05-782003","journal-title":"Blood"},{"issue":"1","key":"7165_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/jocmr4841","volume":"15","author":"AS Ojo","year":"2023","unstructured":"Ojo AS, Odipe OG, Owoseni O (2023) Improving the emergency department management of sickle cell vaso-occlusive pain crisis: the role and options of sublingual and intranasally administered analgesia. J Clin Med Res 15(1):10\u201322. https:\/\/doi.org\/10.14740\/jocmr4841","journal-title":"J Clin Med Res"},{"issue":"1","key":"7165_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/hematology.2020000142","volume":"2020","author":"A Glaros","year":"2020","unstructured":"Glaros A, Brandow AM (2020) Neuropathic pain in sickle cell disease: measurement and management. Hematol Am Soc Hematol Educ Program 2020(1):553\u2013561. https:\/\/doi.org\/10.1182\/hematology.2020000142","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"7165_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2147\/JPR.S185582","volume":"11","author":"SN Uwaezuoke","year":"2018","unstructured":"Uwaezuoke SN, Ayuk AC, Ndu IK, Eneh CI, Mbanefo NR, Ezenwosu OU (2018) Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. J Pain Res 11:3141\u20133150. https:\/\/doi.org\/10.2147\/JPR.S185582","journal-title":"J Pain Res"},{"issue":"4","key":"7165_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ajh.26063","volume":"96","author":"I Osunkwo","year":"2021","unstructured":"Osunkwo I, Andemariam B, Minniti CP et al (2021) Impact of sickle cell disease on patients\u2019 daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY). Am J Hematol 96(4):404\u2013417. https:\/\/doi.org\/10.1002\/ajh.26063","journal-title":"Am J Hematol"},{"issue":"9","key":"7165_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/children11091106","volume":"11","author":"Z Barnawi","year":"2024","unstructured":"Barnawi Z, Thomas R, Peddinti R, Abou Baker N (2024) Inpatient management of pain episodes in children with sickle cell disease: a review. Child (Basel) 11(9):1106. https:\/\/doi.org\/10.3390\/children11091106","journal-title":"Child (Basel)"},{"issue":"3","key":"7165_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/ejh.14017","volume":"111","author":"M Admiraal","year":"2023","unstructured":"Admiraal M, van Daalen J, Ritt MWJ et al (2023) A multimodal pain protocol for treatment of vaso-occlusive crisis in patients with sickle cell disease: implementation and evaluation. Eur J Haematol 111(3):382\u2013390. https:\/\/doi.org\/10.1111\/ejh.14017","journal-title":"Eur J Haematol"},{"key":"7165_CR22","doi-asserted-by":"publisher","first-page":"CD012187","DOI":"10.1002\/14651858.CD012187.pub2","volume":"11","author":"TE Cooper","year":"2019","unstructured":"Cooper TE, Hambleton IR, Ballas SK, Johnston BA, Wiffen PJ (2019) Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. Cochrane Database Syst Rev 11:CD012187. https:\/\/doi.org\/10.1002\/14651858.CD012187.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7165_CR23","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.ctim.2020.102314","volume":"49","author":"SL Tsai","year":"2020","unstructured":"Tsai SL, Bombacie M, Licursi M, Qian Y, Stiles GM, Lee MT (2020) Acupuncture for pediatric sickle cell pain management: a promising non-opioid therapy. Complement Ther Med 49:102314. https:\/\/doi.org\/10.1016\/j.ctim.2020.102314","journal-title":"Complement Ther Med"},{"issue":"3","key":"7165_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s13312-021-2160-3","volume":"58","author":"PC Panda","year":"2021","unstructured":"Panda PC, Mishra NR, Patra CS, Nayak BK, Panda SK (2021) Intravenous acetaminophen vs intravenous diclofenac sodium in management of skeletal vaso-occlusive crisis among children with homozygous sickle cell disease: a randomized controlled trial. Indian Pediatr 58(3):229\u2013232","journal-title":"Indian Pediatr"},{"issue":"10","key":"7165_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/17474086.2022.2131523","volume":"15","author":"R Nobrega","year":"2022","unstructured":"Nobrega R, Carullo V, Thein SL, Quezado ZMN (2022) Subanesthetic ketamine: the way forward for pain management in sickle cell disease patients? Expert Rev Hematol 15(10):887\u2013891. https:\/\/doi.org\/10.1080\/17474086.2022.2131523","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"7165_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/15360288.2018.1468383","volume":"32","author":"N Palm","year":"2018","unstructured":"Palm N, Floroff C, Hassig TB, Boylan A, Kanter J (2018) Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. J Pain Palliat Care Pharmacother 32(1):20\u201326. https:\/\/doi.org\/10.1080\/15360288.2018.1468383","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"7165_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","volume":"18","author":"FA Lubega","year":"2018","unstructured":"Lubega FA, Dehnel PJ, Cherry KB et al (2018) Low-dose ketamine versus morphine for acute severe vaso-occlusive pain in children: a randomized controlled trial. Scand J Pain 18(1):19\u201327. https:\/\/doi.org\/10.1515\/sjpain-2017-0140","journal-title":"Scand J Pain"},{"issue":"2","key":"7165_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/acem.14382","volume":"29","author":"MS Alshahrani","year":"2022","unstructured":"Alshahrani MS, Alkhudair MM, Al-Dossari KH et al (2022) Ketamine administration for acute painful sickle cell crisis: a randomized controlled trial. Acad Emerg Med 29(2):150\u2013158. https:\/\/doi.org\/10.1111\/acem.14382","journal-title":"Acad Emerg Med"},{"issue":"4","key":"7165_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/15360288.2015.1082009","volume":"29","author":"NL Nguyen","year":"2015","unstructured":"Nguyen NL, Kome AM, Lowe DK, Coyne P, Hawks KG (2015) Intravenous lidocaine as an adjuvant for pain associated with sickle cell disease. J Pain Palliat Care Pharmacother 29(4):359\u2013364. https:\/\/doi.org\/10.3109\/15360288.2015.1082009","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"3","key":"7165_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.inpm.2022.100108","volume":"1","author":"BA Howie","year":"2022","unstructured":"Howie BA, Rajput K, Chow R (2022) Regional anesthesia and analgesia in sickle cell pain episodes: a scoping review. Interv Pain Med 1(3):100108. https:\/\/doi.org\/10.1016\/j.inpm.2022.100108","journal-title":"Interv Pain Med"},{"issue":"1","key":"7165_CR31","doi-asserted-by":"publisher","first-page":"R104","DOI":"10.1152\/ajpregu.00021.2018","volume":"315","author":"K Gupta","year":"2018","unstructured":"Gupta K, Jahagirdar O, Gupta K (2018) Targeting pain at its source in sickle cell disease. Am J Physiol Regul Integr Comp Physiol 315(1):R104\u2013R112. https:\/\/doi.org\/10.1152\/ajpregu.00021.2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"7165_CR32","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.10m01063","volume":"13","author":"JM Jerrell","year":"2011","unstructured":"Jerrell JM, Tripathi A, McIntyre RS (2011) Prevalence and treatment of depression in children and adolescents with sickle cell disease: a retrospective cohort study. Prim Care Companion CNS Disord 13(2):PCC.10m01063. https:\/\/doi.org\/10.4088\/PCC.10m01063","journal-title":"Prim Care Companion CNS Disord"},{"issue":"1","key":"7165_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.21873","volume":"86","author":"JM Jerrell","year":"2011","unstructured":"Jerrell JM, Tripathi A, Stallworth JR (2011) Pain management in children and adolescents with sickle cell disease. Am J Hematol 86(1):82\u201384. https:\/\/doi.org\/10.1002\/ajh.21873","journal-title":"Am J Hematol"},{"issue":"8","key":"7165_CR34","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3324\/haematol.2021.280105","volume":"107","author":"J Lopinto","year":"2022","unstructured":"Lopinto J, Gendreau S, Berti E, Bartolucci P, Habibi A, Dessap A (2022) Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis. Haematologica 107(8):1914\u20131921. https:\/\/doi.org\/10.3324\/haematol.2021.280105","journal-title":"Haematologica"},{"issue":"1\u20132","key":"7165_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pain.2009.05.014","volume":"145","author":"W H\u00e4user","year":"2009","unstructured":"H\u00e4user W, Bernardy K, U\u00e7eyler N, Sommer C (2009) Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain 145(1\u20132):69\u201381. https:\/\/doi.org\/10.1016\/j.pain.2009.05.014","journal-title":"Pain"},{"issue":"7","key":"7165_CR36","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/children9071076","volume":"9","author":"KS Plonski","year":"2022","unstructured":"Plonski KS (2022) Acupuncture for pain management in pediatric patients with sickle cell disease. Child (Basel) 9(7):1076. https:\/\/doi.org\/10.3390\/children9071076","journal-title":"Child (Basel)"},{"issue":"1","key":"7165_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/j.pain.0000000000003009","volume":"165","author":"TM Palermo","year":"2024","unstructured":"Palermo TM, Lalloo C, Zhou C et al (2024) A cognitive-behavioral digital health intervention for sickle cell disease pain in adolescents: a randomized controlled multicenter trial. Pain 165(1):164\u2013176. https:\/\/doi.org\/10.1097\/j.pain.0000000000003009","journal-title":"Pain"},{"key":"7165_CR38","doi-asserted-by":"publisher","DOI":"10.2196\/73719","volume":"12","author":"OB Oluwole","year":"2025","unstructured":"Oluwole OB, McGill LS, Gayle K et al (2025) Experiences with a multicomponent digital behavioral pain management intervention for adults with sickle cell disease: qualitative analysis of the CaRISMA trial. JMIR Hum Factors 12:e73719. https:\/\/doi.org\/10.2196\/73719","journal-title":"JMIR Hum Factors"},{"issue":"11","key":"7165_CR39","doi-asserted-by":"publisher","first-page":"e2543421","DOI":"10.1001\/jamanetworkopen.2025.43421","volume":"8","author":"SA Jacob","year":"2025","unstructured":"Jacob SA, Frei-Jones M, Saif-Ur-Rehman S et al (2025) National alliance of sickle cell centers consensus recommendations on sickle cell disease health maintenance: a consensus statement. JAMA Netw Open 8(11):e2543421. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.43421","journal-title":"JAMA Netw Open"},{"issue":"6","key":"7165_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/AJP.0000000000000183","volume":"31","author":"J Schatz","year":"2015","unstructured":"Schatz J, Schlenz AM, McClellan CB et al (2015) Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain 31(6):536\u2013547. https:\/\/doi.org\/10.1097\/AJP.0000000000000183","journal-title":"Clin J Pain"},{"key":"7165_CR41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-413","author":"G Cheminet","year":"2025","unstructured":"Cheminet G et al (2025) Efficacy of a virtual reality headset for managing severe pain during sickle cell vaso-occlusive crisis: A single-center study in adults. Blood. https:\/\/doi.org\/10.1182\/blood-2025-413","journal-title":"Blood"},{"issue":"4","key":"7165_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pmn.2024.04.007","volume":"25","author":"N Matthie","year":"2024","unstructured":"Matthie N et al (2024) Feasibility of In-Home Virtual Reality for Chronic Pain in Sickle Cell Disease. Pain Manag Nurs 25(4):425\u2013431. https:\/\/doi.org\/10.1016\/j.pmn.2024.04.007","journal-title":"Pain Manag Nurs"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07165-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07165-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07165-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:35:26Z","timestamp":1794018926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07165-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7165"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07165-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"441"}}